Literature DB >> 22107151

The tumour suppressor FOXO3 is a key regulator of mantle cell lymphoma proliferation and survival.

Antònia Obrador-Hevia1, Margalida Serra-Sitjar, José Rodríguez, Priam Villalonga, Silvia Fernández de Mattos.   

Abstract

The FOXO3 (Forkhead/winged helix box class O 3) transcription factor is a crucial regulator of haematopoietic cell fate that controls proliferation and apoptosis, among other processes. Despite the central role of FOXO3 as a tumour suppressor and phosphatidylinositol 3-kinase (PI3K)/AKT effector, little is known about its involvement in mantle cell lymphoma (MCL) biology. This study investigated the expression and activity of FOXO3 in MCL cell lines and in primary cultures. We analysed the expression of key FOXO regulators and targets, and studied the effect of modulators of FOXO function on cell viability and apoptosis. FOXO3 was constitutively inactivated in MCL cell lines, and showed cytoplasmic localization in patient-derived cells. PI3K and AKT, but not mammalian target of rapamycin (mTOR), inhibitors induced FOXO3 nuclear translocation and activation in correlation with their impact on MCL proliferation and survival. Moreover, FOXO3-defective cells were resistant to PI3K/AKT inhibitors. Reactivation of FOXO function with a nuclear export inhibitor had a profound effect on cell viability, consistent with FOXO3 nuclear accumulation. Interestingly, inhibition of FOXO3 nuclear export enhanced the effect of doxorubicin. Taken together, our results confirm that FOXO3 is a relevant regulator of proliferation and apoptosis in MCL, and suggest that reactivation of FOXO3 function might be a useful therapeutic strategy in MCL patients.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22107151     DOI: 10.1111/j.1365-2141.2011.08951.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  15 in total

1.  Fine-tuning of FOXO3A in cHL as a survival mechanism and a hallmark of abortive plasma cell differentiation.

Authors:  Clarissa D Osswald; Linka Xie; Hanfeng Guan; Franziska Herrmann; Sarah M Pick; Marion J Vogel; Franziska Gehringer; Fong Chun Chan; Christian Steidl; Thomas Wirth; Alexey Ushmorov
Journal:  Blood       Date:  2018-02-13       Impact factor: 22.113

2.  Serotonin promotes the proliferation of serum-deprived hepatocellular carcinoma cells via upregulation of FOXO3a.

Authors:  Chao Liang; Wei Chen; Xiao Zhi; Tao Ma; Xuefeng Xia; Hao Liu; Qi Zhang; Qida Hu; Yun Zhang; Xueli Bai; Tingbo Liang
Journal:  Mol Cancer       Date:  2013-02-19       Impact factor: 27.401

Review 3.  Transcription factors FOXO in the regulation of homeostatic hematopoiesis.

Authors:  Vijay Menon; Saghi Ghaffari
Journal:  Curr Opin Hematol       Date:  2018-07       Impact factor: 3.284

Review 4.  Concise review: Leukemia stem cells in personalized medicine.

Authors:  Monica L Guzman; John N Allan
Journal:  Stem Cells       Date:  2014-04       Impact factor: 6.277

5.  FOXO3a involvement in the release of TNF-α stimulated by ATP in spinal cord astrocytes.

Authors:  Maosheng Xia; Yue Zhu
Journal:  J Mol Neurosci       Date:  2013-07-17       Impact factor: 3.444

6.  Mechanisms of doxorubicin resistance in hepatocellular carcinoma.

Authors:  Josiah Cox; Steven Weinman
Journal:  Hepat Oncol       Date:  2016-01-01

Review 7.  The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma.

Authors:  Haoran Wang; Wentao Zhang; Jingyi Yang; Keshu Zhou
Journal:  Hematol Oncol       Date:  2021-10-15       Impact factor: 4.850

8.  The D Domain of LRRC4 anchors ERK1/2 in the cytoplasm and competitively inhibits MEK/ERK activation in glioma cells.

Authors:  Zeyou Wang; Qin Guo; Rong Wang; Gang Xu; Peiyao Li; Yingnan Sun; Xiaoling She; Qiang Liu; Qiong Chen; Zhibin Yu; Changhong Liu; Jing Xiong; Guiyuan Li; Minghua Wu
Journal:  J Hematol Oncol       Date:  2016-11-25       Impact factor: 17.388

Review 9.  The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistance.

Authors:  Shang Yao; Lavender Yuen-Nam Fan; Eric Wing-Fai Lam
Journal:  Semin Cancer Biol       Date:  2017-11-24       Impact factor: 15.707

10.  High-Level Expression, Purification and Large-Scale Production of l-Methionine γ-Lyase from Idiomarina as a Novel Anti-Leukemic Drug.

Authors:  Kui-Ying Huang; Hai-Yan Hu; Yan-Lai Tang; Feng-Geng Xia; Xue-Qun Luo; Jian-Zhong Liu
Journal:  Mar Drugs       Date:  2015-08-21       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.